{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:12:50Z","timestamp":1781140370961,"version":"3.54.1"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Peripheral arterial disease (PAD) affects millions of people worldwide. It is a progressive atherosclerotic condition that ranges from asymptomatic disease to severe manifestations such as chronic limb-threatening ischemia and acute limb ischemia. Major risk factors\u2014diabetes mellitus, smoking, hypertension, and hypercholesterolemia\u2014contribute to its pathogenesis by promoting oxidative stress, endothelial dysfunction, and platelet activation. Optimizing antiplatelet and anticoagulant therapy is essential to reducing major adverse cardiovascular events and major adverse limb events. Aspirin and clopidogrel remain standard therapies, but recent trials such as COMPASS and VOYAGER PAD highlight the benefits of combination therapy with low-dose rivaroxaban and aspirin, particularly postrevascularization. Dual antiplatelet therapy is beneficial in select patients, but bleeding risks necessitate individualized treatment approaches. Emerging therapies and procedural advancements offer promising options for high-risk populations, such as those with diabetes, chronic kidney disease, and frailty. This review presents a multidisciplinary approach to PAD management, emphasizing risk stratification and personalized pharmacologic strategies that balance ischemic event prevention with bleeding risk mitigation.<\/jats:p>","DOI":"10.1097\/crd.0000000000000956","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T13:00:59Z","timestamp":1747918859000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Antiplatelet and Anticoagulation Therapy for Peripheral Arterial Disease: Risks Versus Benefits"],"prefix":"10.1097","author":[{"given":"Daniel","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir K.","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhaval B.","family":"Trivedi","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish A.","family":"Parikh","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY"},{"name":"Weill Department of Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaedrea A.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Peterson","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY"},{"name":"Weill Department of Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"R1-20250522","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1161\/CIRCRESAHA.116.303849","article-title":"Epidemiology of peripheral artery disease.","volume":"116","author":"Criqui","year":"2015","journal-title":"Circ Res"},{"key":"R2-20250522","doi-asserted-by":"crossref","first-page":"e1020","DOI":"10.1016\/S2214-109X(19)30255-4","article-title":"Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis.","volume":"7","author":"Song","year":"2019","journal-title":"Lancet Glob Health"},{"key":"R3-20250522","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1161\/ATVBAHA.124.320195","article-title":"Peripheral artery disease: molecular mechanisms and novel therapies.","volume":"44","author":"Athavale","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R4-20250522","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.3390\/ijms21124393","article-title":"Pathophysiology of peripheral arterial disease (PAD): a review on oxidative disorders.","volume":"21","author":"Signorelli","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R5-20250522","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2147\/vhrm.2007.3.2.229","article-title":"Epidemiology, classification, and modifiable risk factors of peripheral arterial disease.","volume":"3","author":"Shammas","year":"2007","journal-title":"Vasc Health Risk Manag"},{"key":"R6-20250522","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1056\/NEJM199202063260605","article-title":"Mortality over a period of 10 years in patients with peripheral arterial disease.","volume":"326","author":"Criqui","year":"1992","journal-title":"N Engl J Med"},{"key":"R7-20250522","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization.","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"R8-20250522","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.jacc.2018.03.008","article-title":"Major adverse limb events and cardiovascular events in patients with peripheral artery disease: the COMPASS trial.","volume":"71","author":"Anand","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R9-20250522","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/j.jvs.2019.02.016","article-title":"Global vascular guidelines on the management of chronic limb-threatening ischemia.","volume":"69","author":"Conte","year":"2019","journal-title":"J Vasc Surg"},{"key":"R10-20250522","first-page":"36","article-title":"Natural history of arteriosclerosis of the lower extremities: hunterian lecture delivered at the Royal College of Surgeons of England on 22nd April 1960.","volume":"28","author":"Bloor","year":"1961","journal-title":"Ann R Coll Surg Engl"},{"key":"R11-20250522","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease.","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"R12-20250522","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jvs.2013.08.003","article-title":"The Society for Vascular Surgery lower extremity threatened limb classification system: risk stratification based on wound, ischemia, and foot infection (WIfI).","volume":"59","author":"Mills","year":"2014","journal-title":"J Vasc Surg"},{"key":"R13-20250522","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1161\/CIRCRESAHA.121.318258","article-title":"Peripheral artery disease: past, present, and future.","volume":"128","author":"Bonaca","year":"2021","journal-title":"Circ Res"},{"key":"R14-20250522","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/clc.23032","article-title":"A risk score assessment tool for peripheral arterial disease in women: from the National Health and Nutrition Examination Survey.","volume":"41","author":"Mansoor","year":"2018","journal-title":"Clin Cardiol"},{"key":"R15-20250522","doi-asserted-by":"crossref","first-page":"e1313","DOI":"10.1161\/CIR.0000000000001251","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS Guideline for the management of lower extremity peripheral artery disease.","volume":"149","author":"Gornik","year":"2024","journal-title":"Circulation"},{"key":"R16-20250522","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1161\/CIRCULATIONAHA.113.000502","article-title":"Approach to the patient with peripheral arterial disease.","volume":"128","author":"Wennberg","year":"2013","journal-title":"Circulation"},{"key":"R18-20250522","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ejvs.2006.09.024","article-title":"Inter-society consensus for the management of peripheral artery disease (TASC II).","volume":"33","author":"Norgren","year":"2007","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"R19-20250522","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14797\/mdcj-8-4-10","article-title":"Criticial limb ischemia: epidemiology.","volume":"8","author":"Davies","year":"2012","journal-title":"Methodist DeBakey Cardiovasc J"},{"key":"R20-20250522","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1161\/CIRCULATIONAHA.107.736108","article-title":"Asymptomatic peripheral arterial disease is associated with more adverse lower extremity characteristics compared to intermittent claudication.","volume":"117","author":"McDermott","year":"2008","journal-title":"Circulation"},{"key":"R21-20250522","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/1358863X10378376","article-title":"Sensitivity and specificity of the ankle\u2013brachial index to diagnose peripheral artery disease: a structured review.","volume":"15","author":"Xu","year":"2010","journal-title":"Vasc Med"},{"key":"R22-20250522","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1161\/CIR.0b013e318276fbcb","article-title":"Measurement and interpretation of the ankle\u2013brachial index: a scientific statement from the American Heart Association.","volume":"126","author":"Aboyans","year":"2012","journal-title":"Circulation"},{"key":"R23-20250522","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.jacc.2023.09.830","article-title":"Disparities in diagnosis, treatment, and outcomes of peripheral artery disease: JACC scientific statement.","volume":"82","author":"McDermott","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"R24-20250522","first-page":"e726","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart association task force on clinical practice guidelines.","volume":"135","author":"Gerhard-Herman","year":"2017","journal-title":"Circulation"},{"key":"R25-20250522","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients.","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"R26-20250522","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: a report from an ADA consensus conference.","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"key":"R27-20250522","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jvs.2014.03.290","article-title":"Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population.","volume":"60","author":"Nehler","year":"2014","journal-title":"J Vasc Surg"},{"key":"R28-20250522","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1161\/CIRCULATIONAHA.117.024469","article-title":"A structured review of antithrombotic therapy in peripheral artery disease with a focus on revascularization: a TASC (intersociety consensus for the management of peripheral artery disease) initiative.","volume":"135","author":"Hess","year":"2017","journal-title":"Circulation"},{"key":"R29-20250522","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2174\/1570161118666200820141131","article-title":"Efficacy and safety of antiplatelet therapies in symptomatic peripheral artery disease: a systematic review and network meta-analysis.","volume":"19","author":"De Carlo","year":"2021","journal-title":"Curr Vasc Pharmacol"},{"key":"R30-20250522","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"R31-20250522","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ahj.2016.01.018","article-title":"Design and rationale for the effects of ticagrelor and clopidogrel in patients with peripheral artery disease (EUCLID) trial.","volume":"175","author":"Berger","year":"2016","journal-title":"Am Heart J"},{"key":"R32-20250522","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jvs.2017.07.065","article-title":"Review of aspirin and clopidogrel resistance in peripheral arterial disease.","volume":"66","author":"Guirgis","year":"2017","journal-title":"J Vasc Surg"},{"key":"R33-20250522","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"key":"R34-20250522","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1161\/CIRCULATIONAHA.120.046048","article-title":"The COMPASS trial: net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin in patients with chronic vascular disease.","volume":"142","author":"Steffel","year":"2020","journal-title":"Circulation"},{"key":"R35-20250522","doi-asserted-by":"crossref","first-page":"e01","DOI":"10.15420\/ecr.2023.40","article-title":"Dual-pathway inhibition with low-dose aspirin and rivaroxaban versus aspirin monotherapy in patients with coronary artery disease and peripheral artery disease: systematic literature review and meta-analysis.","volume":"19","author":"Sibbing","year":"2023","journal-title":"Eur Cardiol"},{"key":"R36-20250522","first-page":"754","article-title":"Rivaroxaban plus aspirin versus aspirin alone in patients with peripheral artery disease after lower extremity revascularization.","volume":"145","author":"Bauersachs","year":"2022","journal-title":"Circulation"},{"key":"R37-20250522","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.121.054835","article-title":"Effect of rivaroxaban and aspirin in patients with peripheral artery disease undergoing surgical revascularization: insights from the VOYAGER PAD trial.","volume":"144","author":"Debus","year":"2021","journal-title":"Circulation"},{"key":"R38-20250522","first-page":"164","article-title":"Antithrombotic therapy in peripheral artery disease: current evidence and future directions.","volume":"10","author":"Canonico","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"key":"R39-20250522","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.jacc.2013.01.004","article-title":"Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF\/AHA guideline recommendations).","volume":"61","author":"Rooke","year":"2013","journal-title":"J Am Coll Cardiol"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T13:01:06Z","timestamp":1747918866000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":38,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000956","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]}}}